Dr Hedy Kindler talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the POLO trial looking at the use of the PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations.
She explains that this trial is the first phase III trial showing that a targeted treatment in a biomarker selective group of pancreatic cancer patients can improve progression free survival.
Dr Kindler reports that patients who received olaparib had a median progression free survival of 7.4 months compared with 3.8 months for those who received the placebo.
Watch the press conference here.
Watch a comment from Dr Suzanne Cole here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.